IOF News

October 28, 2019
During his recent visit to five 5 cities in Argentina, Brazil, Colombia and Mexico, IOF CEO Dr Philippe Halbout held key meetings with IOF member societies, healthcare providers and public policy makers.
October 28, 2019
La oficina regional para América Latina recibió la visita del Dr. Philippe Halbout quien recorrió 5 ciudades de nuestra región con foco en la prevención secundaria de fracturas.
October 28, 2019
IOF member societies in Brazil participated in the Coalition on Osteoporosis in Brazil for the creation of a local public policy focusing on different aspects of osteoporosis.
October 28, 2019
Las sociedades miembro de la IOF en Brasil participan de la Coalición sobre Osteoporosis en Brasil para la creación de una política pública local que se centre en diferentes aspectos de la osteoporosis.
October 28, 2019
The October 22nd Forum, with the theme ‘Cell and gene therapies: a dialogue between patients, physicians and scientists’ presented novel therapies, including endogenous regeneration.
October 24, 2019
On its 10th year anniversary, the Osteoporosis Awareness Society of Kuala Lumpur and Selangor (OASKLS) in Malaysia is stronger than ever, with extensive outreach and important collaborations to raise awareness of osteoporosis.
October 22, 2019
Launched for World Osteoporosis Day, a new edition of the IOF Compendium of Osteoporosis highlights alarming increases in dependency ratios for older people and outlines nine global priorities for fracture prevention.
October 22, 2019
La nueva edición del Compendio de Osteoporosis de la IOF, lanzada para el Día Mundial de la Osteoporosis, destaca incrementos alarmantes en las tasas de dependencia para las personas mayores y describe nueve prioridades globales para la prevención de fracturas.
October 21, 2019
Once again, the Armenian Osteoporosis Society and Dr John Bilezikian hosted a successful International Summit and Symposium in Yerevan with IOF participation. The events brought together more than 60 experts from 25 countries.
October 21, 2019
Committee for Medicinal Products for Human Use (CHMP) has announced a positive opinion recommending marketing authorization for romosozumab for the treatment of severe osteoporosis in postmenopausal women.

Pages